Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy

• Published in: Human molecular genetics Vol. 2; no. 6; p. 737
• Main Authors: Winnard, A V, Klein, C J, Coovert, D D, Prior, T, Papp, A, Snyder, P, Bulman, D E, Ray, P N, McAndrew, P, King, W
• Format: Journal Article
• Language: English
• Published: England 01.06.1993
• Subjects: Adolescent; Adult; Base Sequence; Blotting, Western; Child; DNA Mutational Analysis; Dystrophin - deficiency; Dystrophin - genetics; Exons; Frameshift Mutation; Humans; Male; Models, Genetic; Molecular Sequence Data; Muscular Dystrophies - genetics; Phenotype; Polymerase Chain Reaction; Protein Biosynthesis; Sequence Deletion
• ISSN: 0964-6906
• DOI: 10.1093/hmg/2.6.737

The clinical progression of Duchenne muscular dystrophy (DMD) patients with deletions can be predicted in 93% of cases by whether the deletion maintains or disrupts the translational reading frame (frameshift hypothesis). We have identified and studied a number of patients who have deletions that do not conform to the translational frame hypothesis. The most common exception to the frameshift hypothesis is the deletion of exons 3 to 7 which disrupts the translational reading frame. We identified a Becker muscular dystrophy (BMD) patient, an intermediate, and a DMD patient with this deletion. In all three cases, dystrophin was detected and localized to the membrane. One DMD patient with an inframe deletion of exons 4-18 produced no dystrophin. One patient with a mild intermediate phenotype and a deletion of exon 45, which shifts the reading frame, produced no dystrophin. Two patients with large inframe deletions had discordant phenotypes (exons 3-41, DMD; exons 13-48, BMD), but both produced dystrophin that localized to the sarcolemma. The DMD patient, 113, indicates that dystrophin with an intact carboxy terminus can be produced in Duchenne patients at levels equivalent to some Beckers. The dystrophin analysis from these patients, together with patients reported in the literature, indicate that more than one domain can localize dystrophin to the sarcolemma. Lastly, the data shows that although most patients show correlation of clinical severity to molecular data, there are rare patients which do not conform.